Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy
In short
The stock advanced following an improved assessment delivered by Stifel research analysts. Market participants reacted to the firm changing its stance directly to a Buy rating. This broker upgrade drove a five percent gain in the company's equity value.
Key points
- Analyst rating improvements can drive prompt positive reactions in medical device equitie…: Analyst rating improvements can drive prompt positive reactions in medical device equities.
- Stifel holds a constructive outlook on Tandem Diabetes shares after the upgrade.: Stifel holds a constructive outlook on Tandem Diabetes shares after the upgrade.
- The equity experienced a five percent jump directly tied to Wall Street coverage.: The equity experienced a five percent jump directly tied to Wall Street coverage.